Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 1/20 | 0.52 |
| ▸ | JAK2 | O60674 | 8/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 6/20 | 0.44 |
| ▸ | JAK1 | P23458 | 2/20 | 0.43 |
| ▸ | TYK2 | P29597 | 2/20 | 0.43 |
| ▸ | JAK3 | P52333 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16337556 | 0.87 | CDC7 (0.52) | CDC7JAK2PARP1BTK | |
| SCHEMBL16337964 | 0.84 | JAK2 (0.47) | JAK2BTK | |
| SCHEMBL16337259 | 0.83 | BTK (0.45) | CDC7PARP1BTK | |
| SCHEMBL16337074 | 0.82 | BRD4 (0.52) | CDC7BTK | |
| SCHEMBL16337046 | 0.82 | CHEK1 (0.56) | CDC7BTK | |
| SCHEMBL16337163 | 0.81 | BTK (0.44) | PARP1BTK | |
| SCHEMBL6028814 | 0.81 | PARP1 (0.57) | CDC7JAK2PARP1 | |
| SCHEMBL16336835 | 0.80 | BTK (0.50) | CDC7BTK | |
| SCHEMBL16337354 | 0.80 | BTK (0.47) | JAK2PARP1BTKJAK3 | |
| SCHEMBL16336829 | 0.79 | CDC7 (0.52) | CDC7PARP1BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4008328-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | AbbVie Inc. (US) | 2022-06-08 | — | — | EP | disclosed |
| US-20210179556-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | ABBVIE INC. | 2021-06-17 | — | — | US | disclosed |
| US-20190284135-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | ABBVIE INC. | 2019-09-19 | — | — | US | disclosed |
| EP-3483167-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | AbbVie Inc. (US) | 2019-05-15 | — | — | EP | disclosed |
| EP-3013337-B1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | ABBVIE INC (US) | 2018-10-31 | — | — | EP | disclosed |
| US-20170174624-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | ABBVIE INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-9567339-B2 | Primary carboxamides as BTK inhibitors | ABBVIE INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-20150005279-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | ABBVIE INC. (US) | 2015-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179556-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | BTK, SYK, MYD88 | CDC7 815/4885JAK2 7/4885PARP1 358/4885 |
| US-20150005279-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | BTK, SYK, MYD88 | CDC7 815/4885JAK2 7/4885PARP1 358/4885 |
| US-20190284135-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | BTK, SYK, MYD88 | CDC7 815/4885JAK2 7/4885PARP1 358/4885 |
| US-20170174624-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | BTK, SYK, MYD88 | CDC7 815/4885JAK2 7/4885PARP1 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.